These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 31852271)

  • 21. Serum anti-müllerian hormone level is not altered in women using hormonal contraceptives.
    Li HW; Wong CY; Yeung WS; Ho PC; Ng EH
    Contraception; 2011 Jun; 83(6):582-5. PubMed ID: 21570558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of contraceptive choice on vaginal bacterial and fungal microflora.
    Donders G; Bellen G; Janssens D; Van Bulck B; Hinoul P; Verguts J
    Eur J Clin Microbiol Infect Dis; 2017 Jan; 36(1):43-48. PubMed ID: 27638008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enlarged follicles in women using oral contraceptives.
    Broome M; Clayton J; Fotherby K
    Contraception; 1995 Jul; 52(1):13-6. PubMed ID: 8521709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hormonally impregnated intrauterine systems (IUSs), versus other forms of reversible contraceptives as effective methods of preventing pregnancy.
    French R; Cowan F; Mansour D; Morris S; Hughes D; Robinson A; Proctor T; Summerbell C; Logan S; Guillebaud J
    Cochrane Database Syst Rev; 2001; (2):CD001776. PubMed ID: 11406007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
    Xiao B; Zeng T; Wu S; Sun H; Xiao N
    Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of long-term using of hormonal contraception on anti-Müllerian hormone secretion.
    Kucera R; Ulcova-Gallova Z; Topolcan O
    Gynecol Endocrinol; 2016; 32(5):383-5. PubMed ID: 26651155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ovarian reserve after treatment with alkylating agents during childhood.
    Thomas-Teinturier C; Allodji RS; Svetlova E; Frey MA; Oberlin O; Millischer AE; Epelboin S; Decanter C; Pacquement H; Tabone MD; Sudour-Bonnange H; Baruchel A; Lahlou N; De Vathaire F
    Hum Reprod; 2015 Jun; 30(6):1437-46. PubMed ID: 25801499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Uptake of the levonorgestrel intrauterine system among recent postpartum women in Kenya: factors associated with decision-making.
    Hubacher D; Masaba R; Manduku CK; Veena V
    Contraception; 2013 Jul; 88(1):97-102. PubMed ID: 23566383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Body weight and composition in users of levonorgestrel-releasing intrauterine system.
    Dal'Ava N; Bahamondes L; Bahamondes MV; de Oliveira Santos A; Monteiro I
    Contraception; 2012 Oct; 86(4):350-3. PubMed ID: 22445431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study.
    Jareid M; Thalabard JC; Aarflot M; Bøvelstad HM; Lund E; Braaten T
    Gynecol Oncol; 2018 Apr; 149(1):127-132. PubMed ID: 29482839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of levonorgestrel-releasing intrauterine system use on the cancer risk of the ovary and fallopian tube.
    Soini T; Hurskainen R; Grénman S; Mäenpää J; Paavonen J; Pukkala E
    Acta Oncol; 2016 Nov; 55(11):1281-1284. PubMed ID: 27148621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Matched-pairs analysis of ovarian suppression during oral vs. vaginal hormonal contraceptive use.
    Petrie KA; Torgal AH; Westhoff CL
    Contraception; 2011 Nov; 84(5):e1-4. PubMed ID: 22018131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levonorgestrel-Releasing Intrauterine System for Women With Polycystic Ovary Syndrome: Metabolic and Clinical Effects.
    da Silva AV; de Melo AS; Barboza RP; de Paula Martins W; Ferriani RA; Vieira CS
    Reprod Sci; 2016 Jul; 23(7):877-84. PubMed ID: 26733500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Contraceptive counselling and self-prescription of contraceptives of German gynaecologists: results of a nationwide survey.
    Buhling KJ; Klovekorn L; Daniels B; Studnitz FS; Eulenburg C; Mueck AO
    Eur J Contracept Reprod Health Care; 2014 Dec; 19(6):448-56. PubMed ID: 25112310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantifying effect of combined oral contraceptive pill on functional ovarian reserve as measured by serum anti-Müllerian hormone and small antral follicle count using three-dimensional ultrasound.
    Deb S; Campbell BK; Pincott-Allen C; Clewes JS; Cumberpatch G; Raine-Fenning NJ
    Ultrasound Obstet Gynecol; 2012 May; 39(5):574-80. PubMed ID: 21997961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hormonal intrauterine devices.
    Rybo G; Andersson K; Odlind V
    Ann Med; 1993 Apr; 25(2):143-7. PubMed ID: 8489751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-dose progestin-releasing contraceptives are associated with a higher pain threshold in healthy women.
    Máximo MM; Silva PS; Vieira CS; Gonçalvez TM; Rosa-E-Silva JC; Candido-Dos-Reis FJ; Nogueira AA; Poli-Neto OB
    Fertil Steril; 2015 Nov; 104(5):1182-9. PubMed ID: 26341277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Levonorgestrel-releasing intrauterine system versus a low-dose combined oral contraceptive for treatment of adenomyotic uteri: a randomized clinical trial.
    Shaaban OM; Ali MK; Sabra AM; Abd El Aal DE
    Contraception; 2015 Oct; 92(4):301-7. PubMed ID: 26071673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Women's satisfaction with and ongoing use of hormonal long-acting methods compared to the oral contraceptive pill: Findings from an Australian general practice cluster randomised trial (ACCORd).
    Black KI; McGeechan K; Watson CJ; Lucke J; Taft A; McNamee K; Haas M; Peipert JF; Mazza D
    Aust N Z J Obstet Gynaecol; 2021 Jun; 61(3):448-453. PubMed ID: 33599984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Postoperative levonorgestrel-releasing intrauterine system versus oral contraceptives after gonadotropin-releasing hormone agonist treatment for preventing endometrioma recurrence.
    Cho S; Jung JA; Lee Y; Kim HY; Seo SK; Choi YS; Lee JS; Lee BS
    Acta Obstet Gynecol Scand; 2014 Jan; 93(1):38-44. PubMed ID: 24605384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.